Fresenius Medical (FMS) unveiled its new FME Reignite strategy at its Capital Markets Day in London. FME Reignite centers on value creation, based on three strategic elements: Reignite the core, Reignite growth and innovation and Reignite our culture. Highlights of its strategy include: the introduction of the 5008X dialysis machine with full commercial launch in 2026; by 2030, the company expects to have replaced all existing 2008T dialysis machines in its own U.S. clinic network with the 5008X machine; profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income margins; FME25+ savings target expanded by EUR300M to EUR1.05B by 2027; annual capex of EUR0.8B-EUR1.0B for core business to drive profitable growth; further optimization of capital structure with lowered net leverage ratio target band of 2.5x-3.0x: commitment to return excess capital to shareholders: 30%-40% percent dividend payout plus initial share buyback program of EUR 1B.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 52.50 from EUR 46.50 at Citi
- Fresenius Medical Care Expands U.S. Rollout of 5008X CAREsystem
- Fresenius Medical Care Announces Record Dividend and Strategic Milestones at AGM
- Fresenius Medical price target raised to EUR 43 from EUR 41 at Morgan Stanley
- Fresenius Medical Care Faces FTC Probe and Sells Latin American Clinics Amidst Labor Strikes